Picropodophyllin inhibits tumor growth of human nasopharyngeal carcinoma in a mouse model

Biochemical and Biophysical Research Communications

Volumn 439, Issue 1, 2013, Pages 1-5

  Yin, Shu Cheng ^a,b   Guo, Wei ^b   Tao, Ze Zhang ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Akt; Insulin like growth factor 1 receptor; Nasopharyngeal carcinoma; Nude mouse; Picropodophyllin

Indexed keywords

ANTINEOPLASTIC AGENT; PICROPODOPHYLLIN; PROTEIN KINASE B; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG TARGETING; ENZYME ACTIVITY; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TUMOR VOLUME; TUMOR XENOGRAFT;

AKT; INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR; NASOPHARYNGEAL CARCINOMA; NUDE MOUSE; PICROPODOPHYLLIN;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MICE, INBRED BALB C; MICE, NUDE; NASOPHARYNGEAL NEOPLASMS; NEOPLASM METASTASIS; PHOSPHORYLATION; PODOPHYLLOTOXIN; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1; SOMATOMEDINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA; MUS MUSCULUS;

EID: 84883765859     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.08.050     Document Type: Article

References (27)

1. X. Sun, L.P. Tong, Y.T. Wang, Y.X. Wu, H.S. Sheng, L.J. Lu, W. Wang, Can global variation of nasopharynx cancer be retrieved from the combined analyses of IARC cancer information (CIN) databases?, Plos One 6 (2011).
2. Yoshizaki T., Ito M., Murono S., Wakisaka N., Kondo S., Endo K. Current understanding and management of nasopharyngeal carcinoma. Auris. Nasus. Larynx 2012, 39:137-144.
3. Chan A.T. Nasopharyngeal carcinoma. Ann. Oncol. 2010, 21(Suppl. 7):vii 308-312.
4. Lee A.W., Ng W.T., Chan Y.H., Sze H., Chan C., Lam T.H. The battle against nasopharyngeal cancer. Radiother. Oncol. 2012, 104:272-278.
5. Hui E.P., Leung S.F., Au J.S., Zee B., Tung S., Chua D., Sze W.M., Law C.K., Leung T.W., Chan A.T. Lung metastasis alone in nasopharyngeal carcinoma: a relatively favorable prognostic group. A study by the Hong Kong nasopharyngeal carcinoma study group,. Cancer 2004, 101:300-306.
6. Bennasroune A., Gardin A., Aunis D., Cremel G., Hubert P. Tyrosine kinase receptors as attractive targets of cancer therapy. Crit. Rev. Oncol. Hematol. 2004, 50:23-38.
7. Lemmon M.A., Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010, 141:1117-1134.
8. Xu A.M., Huang P.H. Receptor Tyrosine Kinase Coactivation Networks in Cancer. Cancer Res. 2010, 70:3857-3860.
9. Hewish M., Chau I., Cunningham D. Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine. Recent Pat. Anticancer Drug Discov. 2009, 4:54-72.
10. Girnita A., Girnita L., del Prete F., Bartolazzi A., Larsson O., Axelson M. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res. 2004, 64:236-242.
11. Girnita A., All-Ericsson C., Economou M.A., Astrom K., Axelson M., Seregard S., Larsson O., Girnita L. The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells. Clin. Cancer Res. 2006, 12:1383-1391.
12. Yin S., Girnita A., Stromberg T., Khan Z., Andersson S., Zheng H., Ericsson C., Axelson M., Nister M., Larsson O., Ekstrom T.J., Girnita L. Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma. Neuro. Oncol. 2010, 12:19-27.
13. Klinakis A., Szabolcs M., Chen G., Xuan S., Hibshoosh H., Efstratiadis A. Igf1r as a therapeutic target in a mouse model of basal-like breast cancer. Proc. Natl. Acad. Sci. USA. 2009, 106:2359-2364.
14. Lu X., Wang L., Mei J., Wang X., Zhu X., Zhang Q., Lv J. Picropodophyllin inhibits epithelial ovarian cancer cells in vitro and in vivo. Biochem. Biophys. Res. Commun. 2013, 435:385-390.
15. Menu E., Jernberg-Wiklund H., Stromberg T., De Raeve H., Girnita L., Larsson O., Axelson M., Asosingh K., Nilsson K., Van Camp B., Vanderkerken K. Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model. Blood 2006, 107:655-660.
16. Yin S., Zhou X., Peng T., Li J., Jiang X. Significance of the expression of insulin-like growth factor-1 receptor in nasopharyngeal carcinoma. J. Clin. otorhinolaryngolog Head Neck Surg. 2008, 22:874-877.
17. Lin C.T., Chan W.Y., Chen W., Huang H.M., Wu H.C., Hsu M.M., Chuang S.M., Wang C.C. Characterization of seven newly established nasopharyngeal carcinoma cell lines. Lab. Invest. 1993, 68:716-727.
18. Pollak M. The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology. Clin. Cancer Res. 2012, 18:40-50.
19. Yuan Y., Zhou X., Song J., Qiu X., Li J., Ye L., Meng X., Xia D. Expression and clinical significance of epidermal growth factor receptor and type 1 insulin-like growth factor receptor in nasopharyngeal carcinoma. Ann. Otol. Rhinol. Laryngol. 2008, 117:192-200.
20. Yuan Y.L., Zhou X.H., Song J., Qiu X.P., Li J., Ye L.F. Dual silencing of type 1 insulin-like growth factor and epidermal growth factor receptors to induce apoptosis of nasopharyngeal cancer cells. J. Laryngol. Otol. 2008, 122:952-960.
21. Vasilcanu D., Girnita A., Girnita L., Vasilcanu R., Axelson M., Larsson O. The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway. Oncogene 2004, 23:7854-7862.
22. Duan Z., Choy E., Harmon D., Yang C., Ryu K., Schwab J., Mankin H., Hornicek F.J. Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines. Mol. Cancer Ther. 2009, 8:2122-2130.
23. Wu X., Sooman L., Wickstrom M., Fryknas M., Dyrager C., Lennartsson J., Gullbo J. Alternative cytotoxic effects of the postulated IGF-1R inhibitor picropodophyllin (PPP) in vitro. Mol. Cancer Ther. 2013, 12:1526-1536.
24. Economou M.A., Andersson S., Vasilcanu D., All-Ericsson C., Menu E., Girnita A., Girnita L., Axelson M., Seregard S., Larsson O. Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma. Acta. Ophthalmol. 2008, 86:35-41. Thesis 4.
25. Bensouda Y., Kaikani W., Ahbeddou N., Rahhali R., Jabri M., Mrabti H., Boussen H., Errihani H. Treatment for metastatic nasopharyngeal carcinoma. Eur. Ann. Otorhinolaryngol. Head Neck Dis. 2011, 128:79-85.
26. Ma B.B., Chan A.T. Systemic treatment strategies and therapeutic monitoring for advanced nasopharyngeal carcinoma. Expert Rev. Anticancer Ther. 2006, 6:383-394.
27. Feng X., Aleem E., Lin Y., Axelson M., Larsson O., Stromberg T. Multiple antitumor effects of picropodophyllin in colon carcinoma cell lines: clinical implications. Int. J. Oncol. 2012, 40:1251-1258.